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Abstract 
G protein coupled receptor kinase 2 (GRK2) has a key 
role in cellular function by regulating different 
intracellular mechanisms in a kinase dependent or 
independent manner. In this review we have dealt with the 
recently discovered roles of GRK2 in the regulation of 
cell metabolism. In particular, we have focused on recent 
findings about the mitochondrial role of GRK2 in the 
regulation of energy metabolism. Few findings exist about 
this topic that all concur to identify a mitochondrial 
localization of GRK2, leading to the rising of the 
following question: is GRK2 detrimental or advantageous 
for mitochondrial function? By the review of available 
literature, a new concept arises about GRK2 role into the 
cell,which is that of a stress protein acutely activated by 
cellular stress whose specific subcellular localization, in 
particular mitochondrial localization, results in 
compensatory metabolic responses. Thus, the possibility 
to regulate GRK2 trafficking within the cell is a 
promising strategy to regulate the adaptative effects of the 
kinase on cell metabolism.  
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I. G protein coupled receptor kinase 2 
G protein coupled receptor kinases (GRK) family 
comprises seven serine/threonine kinases which 
phosphorylate and regulate G protein coupled receptors 
(GPCR) (1). GRKs share structural and functional 
similarities (2): a well-conserved central catalytic domain 
is flanked by N-terminal domain, that includes a region of 
homology to regulators of G-protein signaling (RH), with 
weak homology among the members of the different 
subfamilies, and C-terminal domain of variable 
length,which have little or no sequence homology(3, 4). 
GRKs have different tissue distribution, subcellular 
localization, and kinase activity regulation(5, 6). They 
mostly localize at the plasma membrane (7), but recently 
new subcellular localizations have been suggested for 
these kinases (5, 8, 9). GRK2 is known as a cytoplasmic 
protein that translocates to plasma membrane upon GPCR 
stimulation where it specifically recognizes and 
phosphorylates agonist-activated GPCRs leading to 
receptor desensitization (10, 11). Besides its effect on 
GPCR regulation, in the last decade GRK2 has been 
proposed as a multi-functional protein which is involved 
in the regulation of several cellular functions through the 
phosphorylation of cytosolic substrates or in a 
phosphorylation-independent manner through protein-
protein interaction (12-18). Recently, new functions for 
this kinase have been evidenced in several conditions 
(cardiovascular, inflammatory diseases or cancer), 
characterized by increased levels of GRK2 (10, 19-21). 
Such a finding suggests that this kinase could be a 
potential interesting diagnostic marker and/or therapeutic 
target for many conditions. In this review we will discuss 
the role of GRK2 in energy metabolism and 
mitochondrial function. 
 
II. GRK2 and cell metabolism 
An emerging role of GRK2 involves its ability to 
modulate cell metabolism. The first suggestion that GRK2 
is involved in cell metabolism derives from the 
observation that insulin induces up-regulation of the 
kinase (16), which in turn inhibits insulin signaling and 
glucose extraction (16, 19, 22). This observation puts 
GRK2 at the center of the stage as a possible mechanism 
for insulin resistance. Also, conditions associated to 
insulin resistance such as diabetes, hypertension or 
chronic activation of β adrenergic receptor (16), are 
characterized by elevated GRK2 levels. The implications 
for the cell metabolism are identified by transgenic 
studies showing that overexpression of the kinase leads to 
resistance to insulin(23). We have recently identified the 
molecular mechanism by which GRK2 regulates insulin 
signaling. In vitro, insulin induces an increase of GRK2 
levels and causes GRK2–IRS1 association in a time-
dependent manner (16), phosphorylation of IRS1 in 
serine/threonine and inhibition of IRS1 tyrosine 
phosphorylation leading to inhibition of Insulin Receptor 
signaling. Other Authors have also proposed a Galphaq 
dependent mechanism for GRK2 in the regulation of 
insulin signaling (22). If GRK2 upregulation causes 
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insulin resistance, it is legitimate to speculate that its 
inhibition would have positive effects on cellular 
metabolism. Confirmations of such evidence derive from 
models of diabetes. Anis et al. have designed peptide 
inhibitorsof GRK2 that prevent its binding to the substrate 
(24). These peptides correct glucose levels when 
administered in diabetic gerbils. A similar mechanism has 
been confirmed in mouse cardiac myocytes, where GRK2 
causes IRS-1 phosphorylation at serine 307 (25). In 
spontaneously hypertensive rats, chronic treatment with a 
similar inhibitor of GRK2 kinase activity, Ant-124, not 
only leads to an amelioration of the glucose homeostasis 
and IRS1 tyrosine phosphorylation, but also to the 
reduction of the blood pressure levels (16). These findings 
are in agreement to other literature showing that the 
inhibition of GRK2 clearly delays the reduction of 
glucose uptake and protects insulin signaling in the heart, 
preserving cardiac dimension and function (25). This 
nurtures a novel scenario in which GRK2 inhibition might 
correct impaired metabolism in those conditions 
characterized by poor energy utilization by the cell, such 
as heart failure. In particular, it is known that GRK2 
inhibition obtained through means of transgenic 
expression of the truncated mutant which prevents GRK2 
localization on membranes (GRK2-ct) or deletion of 
GRK2 gene is beneficial for the failing heart. 
Nevertheless, this benefit is thought to be dependent upon 
inhibition of beta adrenergic receptors in the heart. We 
can also speculate that GRK2 inhibition leads to improved 
cardiac utilization of energy. Indeed, a recent paper shows 
that in the course of development of heart failure impaired 
glucose metabolism precedes cardiac contractility in mice 
with myocardial infarction (25). These findings support 
the idea that the inhibition of the kinase activity of GRK2 
could be a potential target for therapeutics and, as 
corollary, GRK2 is tout court deleterious for the cell. 
However, recent evidences challenge this view, as it is 
emerging that GRK2 exerts different effects within the 
cell depending on its localization, cell type, stimuli and 
physio-pathological context (8, 21, 26-28). 
 
III. GRK2 and energy metabolism 
Beside the known localization of GRK2 in plasma 
membrane and cytosol, recently an unexpected 
localization of GRK2 within the cell has been shown.  
Indeed, it has been demonstrated that GRK2 possesses the 
ability to localize in mitochondria in different cell lines 
and contexts (8, 29, 30). Such mitochondrial localization 
suggests a potential role of GRK2 in the regulation of 
energy metabolism but to date there are only few and 
apparently contradictory reports on this topic. Trying to 
sort out the knowledge available, two major evidences are 
accumulating: 
1) The conditions that facilitate GRK2 accumulation in 
the mitochondria. It is becoming clear that in the resting 
condition, GRK2 is in mitochondria. This acquisition is 
supported by evidences gathered with different 
technologies, including western blotting, 
immunofluorescence, electron microscopy(8, 29-31). 
What is interesting, is that different conditions can 
modulate the amount of mitochondrial GRK2 levels, and 
in particular stressors events can accelerate this process. 
In macrophages, GRK2 levels in mitochondria increase 
during inflammation or LPS stimulation, facilitating 
biogenesis and restoring mitochondrial function (31). 
Accordingly, Obrenovich et al. showed that in the early 
pathogenesis of Alzheimer Disease (AD) and in ischemia 
reperfusion brain injury models,GRK2 accumulates in 
damaged mitochondria (30). GRK2 localization to 
mitochondria appears to be a generalized reactive 
response in different tissues. Indeed, Chen et al. showed 
that in hearts in vivo and in cultured myocytes, 
GRK2 localizes into mitochondria after an ischemia-
reperfusion insult (29). Chen and co-authors also suggest 
a potential mechanism by which the kinase is able to 
traffic to mitochondria. In particular, they demonstrate 
that phosphorylation at residue Ser670 within the 
carboxyl-terminus of GRK2 by extracellular signal-
regulated kinases (ERK) allows GRK2 to bind the heat 
shock protein 90 (HSP90), which chaperones the 
kinase to mitochondria (29). Once again, the involvement 
with HSP90 is supportive for a stress related response put 
in place by the cell in a fast manner. Although Chen data 
illustrate the likely mechanism of mitochondrial transport 
of GRK2, they do not provide any insight on the 
mechanisms that anchor GRK2 on mitochondria. On this 
issue, we have demonstrated that GRK2 recognizes 
several protein partners, which can be phosphorylated 
within the mitochondria by the kinase, although so far no 
data are available to distinguish the identities of such 
partners(8). Mitochondrial fraction analysis suggests that 
indeed GRK2 co-localizes with proteins of the 
intermembrane space, although once again there is only 
one report available(8). If confirmed, these data are 
consistent with a different mechanism of localization of 
GRK2 in plasma membrane and in mitochondria. In 
particular, GRK2 docks on plasma membrane through 
means of the carboxy-terminal domain, interacting with 
 subunit of G proteins (32). Such mechanism is so well 
established that therapeutic strategies aimed to reduce 
GRK2 mediated membrane receptor desensitization are 
based on truncated mutants of GRK2 that prevent the 
kinase interaction with G subunit (GRK2-ct). 
Interestingly, this mechanism does not appear to be 
relevant to mitochondrial localization of GRK2 since 
transgenic overexpression of GRK2-ct that removes 
GRK2 from plasma membrane does not reduce GRK2 
localization in mitochondria. This is evident from our 
work (31)and is confirmed also in Chen paper(29), where 
mitochondrial lysates from neonatal rat cardiac myocytes 
in resting conditions, infected with an adenovirus 
encoding for GRK2-ct, still presented an unchanged 
amount of GRK2. Therefore, it is fair to conclude that 
GRK2-ct is not the mechanism for GRK2 accumulation in 
mitochondria. 
2) The role of GRK2 in mitochondria. This issue is 
probably more controversial, as different experiments 
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performed with different techniques and in different 
models have showed apparently contradicting results. In 
particular, we have demonstrated that GRK2 localizes 
into mitochondria of HEK-293 cells and enhances 
mitochondrial biogenesis thus leading to an increase of 
ATP cellular content (8). The overexpression of GRK2 
induces the accumulation of the kinase in mitochondria 
with a consequent increase of mitochondrial biogenesis 
antagonizing ATP loss after hypoxia/reperfusion (8). A 
similar finding, obtained with an opposite strategy, shows 
that GRK2 removal from the skeletal muscle in vivo leads 
to reduced ATP production and impaired tolerance to 
ischemia (8). Altogether these findings propose a 
“positive” regulatory role of GRK2 for mitochondrial 
biogenesis and ATP generation (31).  
Using GRK2-ct to inhibit GRK2, Chen et al. show that 
ischemia/reperfusion injury is no longer able to induce 
GRK2 accumulation in mitochondria. The final result is 
the reduction of mitochondrial apoptosis. This finding is 
interpreted by the Authors as the evidence that GRK2 
mitochondrial accumulation causes apoptosis, and that 
preventing this trafficking favors cell survival. The 
finding is far from being conclusive and offers alternative 
interpretations. Indeed, GRK2-ct is well known for its 
regulatory effects on intracellular signaling, as it blocks 
G signaling and activation of ERK(33), which is 
believed to be the mechanism of GRK2 association to 
HSP90, but also causes inhibition of pro-apoptotic GRK2-
independent signaling such as PI3K pathway(29). From 
Chen’s study it is not possible to determine the 
chronologic order of events that takes place when GRK-
ct is expressed in cells subjected to a stress. It might as 
well be that  GRK2-ct, by preventing G and PI3K 
related signaling, attenuates the stressor signal within the 
cell, therefore reducing the reactive stress responses, 
which includes GRK2 accumulation in mitochondria. This 
hypothesis needs confirmation in studies where other 
inhibiting strategies for GRK2 are put in place, i.e. GRK2 
silencing or pharmacological inhibition of the catalytic 
activity, or disruption of  GRK2/HSP90 interaction. On 
the other end,  we have demonstrated that in LPS treated 
macrophages,GRK2-ct is beneficial to the macrophage 
functionality and survival, by restoring mitochondrial 
function in a GRK2 dependent manner. Indeed, down-
regulation of GRK2 levels by specific siRNA, reduces 
also GRK2 levels in mitochondria. In this condition, none 
of the LPS dependent inflammatory phenotypes could be 
restored by the overexpression of GRK2-ct (31). This 
clearly suggests that mitochondrial effects of GRK2-ct are 
strictly dependent on mitochondrial accumulation of 
GRK2 and confirms the protective role of mitochondrial 
GRK2 in inflammation probably through its ability to 
restore mitochondrial biogenesis. Our report clarifies the 
function of GRK2-ct demonstrating that it is a regulator of 
GRK2 subcellular localization rather than an inhibitor of 
the catalytic activity of the kinase, leading to a reduction 
of its effects on plasma membrane and an increase of its 
effects in mitochondria (Figure 1).  
 
 
Conclusions and perspectives 
It is now clear that GRK2 is able to localize in 
mitochondria (8, 29-31) but the role of the kinase in this 
organelle is still controversial. Is GRK2 detrimental or 
advantageous for cell function? It is difficult to find an 
answer to this question at this stage, giving the multiple 
roles of GRK2 within the cell. For sure, the perceived role 
of the kinase within the cell is reshaping. Old evidence 
together with novel finding propose this kinase as an 
important adaptive mechanism to stress, such as receptor 
dependent and independent stimuli. It has been 
demonstrated that total knock-out of GRK2 in mice is 
lethal for embryo development (34), thus the generation 
of transgenic mice with specific organ targeted knock out 
of GRK2 has been required to perform in vivo studies. 
This suggests that GRK2 is critical for cell survival. 
Based on CRE-pLox technique, it has been showed that 
the removal of GRK2 from specific tissues such as 
endothelium (35) or cells of the myeloid lineage (36) 
activates pro-inflammatory phenotypes in mice, thus 
confirming that GRK2 is protective respect to 
inflammation. Moreover, it was recently demonstrated 
that the endothelium-specific knockout of GRK2 is 
associated with impaired angiogenesis (37). Accordingly, 
GRK2 deficiency in endothelial cells in vitro  increases 
inflammatory signaling and enhances leukocyte 
recruitment to  
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Figure 1: A-B) Subcellular localization and function of 
GRK2 in response to stress: effects of GRK2-ct. A) In 
response to stress, GRK2 moves within different cellular 
compartments in a time dependent manner. On plasma 
membrane, GRK2 interacts with G subunit, leading to 
phosphorylation and desensitization of GPCRs, and with 
PI3K to facilitate its recruitment to the membrane upon 
agonist stimulation..is also able to transduce  signaling 
independently, i.e. it activates PI3K and ERK. This latter, 
on turn, phosphorylates GRK2 in Ser 670 facilitating the 
interaction with HSP90, which shuttles the kinase towards 
mitochondria. Here GRK2 interacts with unknown 
mitochondrial partners to regulate mitochondrial 
function. In the cytosol, GRK2 interacts with several 
proteins (i.e AKT, Actinin, p38MAPK, IB) to 
regulate GPCR independent intracellular signaling. B) 
GRK2-ct binds and displaces GRK2 from plasma 
membrane, exerting several effects: 1) it inhibits GRK2-
dependent desensitization of GPCRs2) prevent PI3K 
recruitment to plasma membrane;2)blocks -dependent 
signaling, such as the activation of ERK,  PI3K, and 
AKT signaling. 4), GRK2-ct makes GRK2 available in 
other cellular compartments, such as cytosol and 
mitochondria. 
 
activated endothelial cells (38). Furthermore, GRK2 
accumulates in mitochondria to restore mitochondrial 
function both in HEK-293 and RAW264.7 (8, 31), thus 
suggesting that it is a positive regulator of energy 
metabolism.  
As all the adaptive mechanisms, the effect is helpful at the 
very beginning, but then, eventually, becomes detrimental 
for the physiology of the cell. Indeed, several reports 
suggest a deleterious effect of increased levels of GRK2 
in the development of heart failure and insulin resistance 
when it is increased on plasma membranes (16, 25) and in 
cardiac cells GRK2 localization in mitochondria seems to 
be associated with cell death (29). Subcellular localization 
of the kinase might in the future pose the strategy for 
selective inhibition of the kinase, and the possibility to 
modulate GRK2 accumulation within cell organelles 
could be an useful approach to regulate its negative or 
positive effects on cell function in a time dependent 
manner. In this context, GRK2-ct could be an useful 
strategy to regulate GRK2 subcellular localization and its 
associated effects. However several issues remain still 
unsolved: Which is the GRK2 partner to anchor into 
mitochondria? Which is the mitochondrial signaling that 
is affected by GRK2? Further studies are needed to 
answer to these questions to increase the knowledge on 
the role of GRK2 in mitochondria and elaborate an 
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